Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches

  • Number of patients reached in 2024 jumps 8% to 66 million
  •  R&D investments rise to EUR 6.2 billion, 23.2% of group net sales
  • Company prepares new product launches starting in 2025

Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion.

“As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors. “It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.”

Human Pharma: investing in existing products and new launches

Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by JARDIANCE® and OFEV®. Sales of JARDIANCE®, which is now also available for treatment of chronic kidney diseases, in addition to type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. OFEV®, which is used to treat idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion. 

The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit’s net sales.

“If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,” said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. “With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.”

After positive data from pivotal studies, the company is preparing multiple new product launches, starting this year with potential launches of zongertinib and nerandomilast.

Nerandomilast has the potential to advance care for patients with Idiopathic Pulmonary Fibrosis (FIBRONEER™-IPF) and Progressive Pulmonary Fibrosis (FIBRONEER™-ILD).  Full data from both phase III FIBRONEER™-trials, which met their primary endpoint, will be presented in the coming months.

If approved, zongertinib would be the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients. Zongertinib’s development was accelerated due to positive Phase 1b Beamion LUNG-1 trial data, which showed a response rate of 71% (95% CI, 60–80), p<0.0001**, and disease control rate of 93%. It was generally well tolerated, with a low toxicity-related discontinuation rate (3%). Additional studies in HER2-altered solid tumors are ongoing. 

Both zongertinib and nerandomilast have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval.

Animal Health: rapid response against transboundary animal diseases

Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides NEXGARD® continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion.  

Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease.  These diseases pose a significant risk to animal health, impede global trade, and constrain food supply.

Sustainable Development

Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations (Scope 1 and 2) by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs. 

As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The “Angels” initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date.

Outlook

The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects.

* sales growth numbers are adjusted for currency effects
**one-sided p-value from a z-test of the null hypothesis ORR ≤30%

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.   

Attachment

  • Boehringer Laboratory

Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches


THỦ THUẬT HAY

7 cách tải video YouTube nhanh, tiện lợi nhất có thể

Bạn đang loay hoay cách tải video Youtube về điện thoại hoặc máy tính của mình? Bạn tìm cách tải video trên Youtube về máy tính hoặc điện thoại của mình nhanh nhất có thể?

Intel sẽ sớm tung ra bộ vi xử lý Core thế hệ thứ 13 Raptor Lake

Intel sẽ sớm tung ra bộ vi xử lý Core thế hệ thứ 13, có tên mã là Raptor Lake, với kiến trúc và quy trình tương tự.

Hướng dẫn download phim từ Netflix trong Windows 10

Gần đây, Netflix đã hỗ trợ tải phim trên các thiết bị Windows, do đó, bạn có thể xem phim offline trên PC hoặc laptop một cách dễ dàng. Dưới đây, chúng tôi sẽ hướng dẫn bạn đọc cách tải phim từ Netflix trong Windows 10.

Hướng dẫn cài đặt Adobe Flash trên trình duyệt Vivaldi

Hiện nay khá nhiều trang web sử dụng HTML 5, để có thể truy cập được các trang web này yêu cầu bạn phải cài đặt Adobe Flash.Trong trường hợp nếu bạn duyệt web trên trình duyệt Vivaldi, các trang web sẽ yêu cầu bạn cài

3 cách để bảo vệ toàn diện trên môi trường Internet

Vấn đề bảo mật khi dùng Internet luôn là một trong những điều mà người dùng quan tâm nhất, nhưng dữ liệu của bạn rất dễ bị rò rỉ và bán cho những nhà quảng cáo, do đó, hôm nay, TCN sẽ giới thiệu cho các bạn ba công cụ

ĐÁNH GIÁ NHANH

Tất cả những gì bạn cần đều được trang bị trên Galaxy Note9

Từ những tác vụ cơ bản mượt mà, cho đến trải nghiệm tuyệt đỉnh nhờ hiệu năng vượt trội, màn hình kích thước cực lớn, hiển thị rõ ràng, sắc nét, rực rỡ và một chiếc bút S Pen đi kèm đầy kỳ diệu. Không phải thiết bị nào

So sánh Xiaomi Mi Pad 5 và Realme Pad: Lựa chọn nào tốt hơn cho người dùng?

Xiaomi Mi Pad 5 và Realme Pad là hai chiếc máy tính bảng thuộc phân khúc tầm trung mới được trình làng gần đây. Dù có mức giá phải chăng song chúng vẫn được trang bị nhiều tính năng thú vị. Vậy đâu là lựa chọn tốt hơn

So sánh Galaxy Z Fold3 5G và Galaxy S21 Ultra 5G: Giá bán gấp hai liệu có mang đến trải nghiệm gấp đôi?

Giữa Galaxy Z Fold3 5G vừa ra mắt và Galaxy S21 Ultra ra mắt đầu năm nay, đâu là chiếc điện thoại chất lượng nhất? Hãy cùng chúng tôi so sánh Galaxy Z Fold3 5G và Galaxy S21 Ultra 5G để có câu trả lời thích hợp nhất.